261 related articles for article (PubMed ID: 30048046)
1. Design and Conduct Considerations for First-in-Human Trials.
Shen J; Swift B; Mamelok R; Pine S; Sinclair J; Attar M
Clin Transl Sci; 2019 Jan; 12(1):6-19. PubMed ID: 30048046
[TBL] [Abstract][Full Text] [Related]
2. A brief survey of first-in-human studies.
Wexler D; Bertelsen KM
J Clin Pharmacol; 2011 Jul; 51(7):988-93. PubMed ID: 20671293
[TBL] [Abstract][Full Text] [Related]
3. Commentary on the EMA Guideline on strategies to identify and mitigate risks for first-in-human and early clinical trials with investigational medicinal products.
van Gerven J; Bonelli M
Br J Clin Pharmacol; 2018 Jul; 84(7):1401-1409. PubMed ID: 29451320
[No Abstract] [Full Text] [Related]
4. Current nonclinical testing paradigms in support of safe clinical trials: An IQ Consortium DruSafe perspective.
Butler LD; Guzzie-Peck P; Hartke J; Bogdanffy MS; Will Y; Diaz D; Mortimer-Cassen E; Derzi M; Greene N; DeGeorge JJ
Regul Toxicol Pharmacol; 2017 Jul; 87 Suppl 3():S1-S15. PubMed ID: 28483710
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. First-in-human dose: current status review for better future perspectives.
Mishra A; Sarangi SC; Reeta K
Eur J Clin Pharmacol; 2020 Sep; 76(9):1237-1243. PubMed ID: 32488334
[TBL] [Abstract][Full Text] [Related]
7. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
Muller PY; Brennan FR
Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
[TBL] [Abstract][Full Text] [Related]
8. A translational model-based approach to inform the choice of the dose in phase 1 oncology trials: the case study of erdafitinib.
Tosca EM; Terranova N; Stuyckens K; Dosne AG; Perera T; Vialard J; King P; Verhulst T; Perez-Ruixo JJ; Magni P; Poggesi I
Cancer Chemother Pharmacol; 2022 Jan; 89(1):117-128. PubMed ID: 34786600
[TBL] [Abstract][Full Text] [Related]
9. Safety in FIH Trials: A Summary of the Symposium "Fatal Drug Trial in Phase 1: Understanding Risk, Subject Safety, Timelines, and Cost".
Greenberg HE; van Iersel MT; Westrick ML; Smith WB
Ther Innov Regul Sci; 2017 May; 51(3):276-284. PubMed ID: 30231706
[TBL] [Abstract][Full Text] [Related]
10. Preclinical research: Design animal studies better.
Macleod MR
Nature; 2014 Jun; 510(7503):35. PubMed ID: 24899295
[No Abstract] [Full Text] [Related]
11. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
Lawrence YR; Vikram B; Dignam JJ; Chakravarti A; Machtay M; Freidlin B; Takebe N; Curran WJ; Bentzen SM; Okunieff P; Coleman CN; Dicker AP
J Natl Cancer Inst; 2013 Jan; 105(1):11-24. PubMed ID: 23231975
[TBL] [Abstract][Full Text] [Related]
12. Statistical considerations for preclinical studies.
Aban IB; George B
Exp Neurol; 2015 Aug; 270():82-7. PubMed ID: 25725352
[TBL] [Abstract][Full Text] [Related]
13. Methodologic guidelines for the design of high-dose chemotherapy regimens.
Margolin K; Synold T; Longmate J; Doroshow JH
Biol Blood Marrow Transplant; 2001; 7(8):414-32. PubMed ID: 11569887
[TBL] [Abstract][Full Text] [Related]
14. Shared Learnings on the New EMA First-in-Human and Early Clinical Trial Guideline: Proceedings From a DIAlogue Session at DIA Europe 2018.
van der Laan JW; Benson CT; Janssens W; Bos J; Stahl E; Brady JT; Wändel-Liminga U; Corriol-Rohou S; Forster R; Hartmann A; Pertel PE; Robertson SM; Silva-Lima B; Malik RE; Chibout SD
Ther Innov Regul Sci; 2020 Mar; 54(2):462-467. PubMed ID: 32072587
[TBL] [Abstract][Full Text] [Related]
15. The New First-in-Human EMA Guideline: Disruptive or Constructive? Outcomes From the First EUFEMED Discussion Forum.
Breithaupt-Grögler K; Hardman T; de Hoon J; Donazzolo Y; Rottey S; Sourgens H; Stringer S
Front Pharmacol; 2019; 10():398. PubMed ID: 31068811
[TBL] [Abstract][Full Text] [Related]
16. Adaptive designs in clinical trials: from scientific advice to marketing authorisation to the European Medicine Agency.
Collignon O; Koenig F; Koch A; Hemmings RJ; Pétavy F; Saint-Raymond A; Papaluca-Amati M; Posch M
Trials; 2018 Nov; 19(1):642. PubMed ID: 30454061
[TBL] [Abstract][Full Text] [Related]
17. First-in-human trial participants: not a vulnerable population, but vulnerable nonetheless.
Dresser R
J Law Med Ethics; 2009; 37(1):38-50. PubMed ID: 19245601
[TBL] [Abstract][Full Text] [Related]
18. Translation of innovative designs into phase I trials.
Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
[TBL] [Abstract][Full Text] [Related]
19. Scientific and Regulatory Policy Committee Points to Consider*: Approaches to the Conduct and Interpretation of Vaccine Safety Studies for Clinical and Anatomic Pathologists.
Sellers RS; Nelson K; Bennet B; Wolf J; Tripathi N; Chamanza R; Perron Lepage MF; Adkins K; Laurent S; Troth SP
Toxicol Pathol; 2020 Feb; 48(2):257-276. PubMed ID: 31594486
[TBL] [Abstract][Full Text] [Related]
20. Translational and pharmacokinetic-pharmacodynamic application for the clinical development of GDC-0334, a novel TRPA1 inhibitor.
Chan P; Ding HT; Liederer BM; Mao J; Belloni P; Chen L; Gao SS; Joseph V; Yang X; Lin JS; Mitra MS; Putnam WS; Quartino A; Bauer RN; Pan L
Clin Transl Sci; 2021 Sep; 14(5):1945-1954. PubMed ID: 34058071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
